‘Clinical Diabetology’: Highlights of 2023 and Future Direction

Greetings from the Editorial Board of ‘Clinical Diabetology’!

We have successfully completed the second year of ‘Clinical Diabetology’ (CD) after a significant change in the leadership and editorial boards at CD in January 2022 [1]. The Editor-in-Chief, Dr. Viral N. Shah, supported by new editorial team, has brought the Journal to a new height, and converted CD to the international platform. We are pleased to share some of our recent achievements and insights with readers of the Journal.

We continue to see increase in submissions to ‘Clinical Diabetology’ from around the world. Compared to 2022, the number of submissions to CD has grown further. However, we strive to maintain the quality of research publication and thus, the rejection rate has increased to over 40%.

In 2023, Editors were able to keep average ‘submission to early publication’ time of around 90 days, which was one of our first objectives (Fig. 1). Achieving this would have not been possible without contributions of expert reviewers helping us select the best research articles. We will continue to acknowledge our reviewers and provide them with a reviewer certificate as a token of our appreciation.

Readers of ‘Clinical Diabetology’ may have noticed that each issue has been standardized for structure with the goal of including an editorial, 5–6 original articles,
1–2 review articles, and 1–2 letters. We believe these numbers will escalate in months to come, however without compromise to quality.

After updating author instructions to facilitate manuscript formatting as well as enforcing some detailed policies as per COPE/ICMJE recommendations, we have recently modernized CD’s website to make the website informative and user-friendly. Hopefully, this will be appreciated by our readers.

We have observed growth of the numbers of both downloads and views of articles published in CD. Table 1 highlights the top three most downloaded research articles in the year 2023.

So, plenty is going on at ‘Clinical Diabetology’. Editors and the Publisher, however, are well aware of tasks still ahead of us. One of which is attracting more submissions from WHO Region of the Americas (AMRO), further technical optimization of review process, as well as reducing article production time. We invite you to join forces with us by submitting your research contributions, citing our most relevant papers and/or become a reviewer.

### Conflict of interest

Dr. Shah is a Editor-in-Chief for ‘Clinical Diabetology’. He reported receiving research grant from NovoNordisk, Alexion, Tandem Diabetes Care, and insulin Honoraria from Sanofi, NovoNordisk, Embecta, Dexcom, Tandem Diabetes Care, Insulet, unrelated to this publication. Dr. Stolarczyk is a consultant advisor to Via Medica, publisher of scientific journals, including ‘Clinical Diabetology’.

### REFERENCES


<table>
<thead>
<tr>
<th>Issue</th>
<th>Title</th>
<th>First author</th>
<th>Number of views</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023;1</td>
<td>The Promise of Diabetes Technologies</td>
<td>Ebekozien O</td>
<td>2553</td>
<td>[2]</td>
</tr>
<tr>
<td>2023;1</td>
<td>&quot;My Friend Diabetes Carbohydrate-Bolus Calculator&quot;: User Experiences of a Bolus Calculating Carbohydrate Counting Mobile App for People with Type 1 Diabetes</td>
<td>Karakuş K</td>
<td>2426</td>
<td>[3]</td>
</tr>
<tr>
<td>2023;1</td>
<td>Significant Improvement in Glycemic Control after Initiation of AHCL in Children with Type 1 Diabetes: A Single Center Prospective Study</td>
<td>Yeşiltepe Mutlu</td>
<td>2422</td>
<td>[4]</td>
</tr>
</tbody>
</table>